Global WholeHealth Partners Corp (GWHP-OTC) Acquires Rights to Distribute & Sell a 2nd COVID-19 Vaccine - The Pfizer-BioNTech

The Pfizer-BioNTech Was Found to be More Than 95% Effective Against Severe Disease or Death From Variants

Company Now Has the Rights to Distribute & Sell Both the Pfizer-BioNTech and J&J COVID-19 Vaccines; Respectively, the Most Effective and the Most Convenient Vaccines

Global WholeHealth Partners Corp. (OTC: GWHP), a company that offers one of the largest lines of COVID-19 tests including SARS-CoV-2 viruses and that states that its Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses, and that recently announced that they had acquired the rights to be able to distribute and sell Johnson & Johnson’s COVID-19 vaccine, today announced that they have now, also, acquired the rights to sell and distribute Pfizer’s vaccine.

As with the Johnson & Johnson, the Pfizer-BioNTech 8K was filed on June 10, 2021, for the J&J rights and Pfizer-BioNTech, the Company has also filed an 8K on June 16, 2021, stating that “Effective June 4, 2021, Global WholeHealth Partners Corporation (the ‘Company’) was granted the rights from Nunzia Pharmaceutical Inc. (‘Nunzia’) to distribute and sell the Pfizer-BioNTech COVID-19 Vaccine. The Company will serve as a broker for Nunzia and follow the same sales order processing as used by Nunzia in connection with the distribution and sale of the Vaccine.”[1]

On December 11, 2020, Pfizer became the first COVID-19 vaccine to gain an FDA EUA, after the company reported positive clinical trial data, which included news that the vaccine was up to 95% effective at preventing symptomatic disease. According to Yale Medicine[2], they said that: “(Pfizer’s vaccine has a) 95% efficacy in preventing COVID-19 in those without prior infection. The researchers report that the vaccine was equally effective across a variety of different types of people and variables, including age, gender, race, ethnicity, and body mass index (BMI)—or presence of other medical conditions. In clinical trials, the vaccine was 100% effective at preventing severe disease… and in early May, the Pfizer-BioNTech vaccine was found to be more than 95% effective against severe disease or death from the variants first detected in the United Kingdom (B.1.1.7, or the Alpha variant) and South Africa (B.1.351, or the Beta variant) in two studies based on real-world use of the vaccine. While the efficacy against infection varied between the two studies, both also showed the vaccine provides strong protection.”

The Company already offers one of the largest lines of COVID-19 tests, including the strains identified in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) strain contains multiple mutations, most reflected in the S gene, which encodes the spike protein.

Mr. Charles Strongo, the CEO and Chairman of WholeHealth Products Inc., said: “Global will now have both J&J’s extremely convenient 1-shot vaccine, and we now have the rights to the Pfizer-BioNTech vaccine, which is generally considered the highest efficacy.”

About Global WholeHealth Partners Corp

GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians' offices, and medical clinics in the US and abroad. The Company has the capacity to deliver hundreds of thousands of tests, and can ramp up to 1 million tests per day and the Company presently has 56 products FDA approved and many are Approved for OTC use, and 9 POC products approved by the FDA, many of which are Approved for OTC use, and 15 POC products approved by the CLIA WAIVED FDA.

For more information please go to:www.gwhpcorp.com

Sales: 714-392-3423, Sales@gwhpcorp.com

Media: Charles Strongo 714-392-9752

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.